Phapros Records 113% Net Profit Growth in First Quarter of 2026
Jakarta (ANTARA) - The pharmaceutical company, a subsidiary of state-owned enterprise PT Kimia Farma (Persero) Tbk, PT Phapros Tbk (PEHA), recorded a 113% year-on-year net profit growth in the first quarter of 2026.
Acting President Director of Phapros, Ida Rahmi Kurniasih, stated in her comments quoted in Jakarta on Sunday that the company’s profitability in the first quarter of 2026 was supported by a 10.17% increase in sales to Rp221.09 billion compared to the same period in 2025 of Rp200.67 billion.
On the other hand, the cost of goods sold (COGS) in the first quarter of 2026 only rose by 5.04%, lower than the sales growth.
As a result, gross profit increased by 16.59% to Rp103.96 billion compared to Rp89.17 billion in the first quarter of 2025.
Meanwhile, Phapros’s operating expenses for January-March 2026 remained relatively stable, rising only 7.35% year-on-year.
The significant sales growth and the ability to maintain stability in COGS and operating expenses enabled Phapros to record a net profit of Rp761.49 million in the first quarter of 2026, up 112.86% from a loss of Rp5.92 billion in the same period the previous year.
This early 2026 trend continues the net profit growth achieved in 2025 of 109% year-on-year.
According to her, the company consistently implements strategies to optimise all sales channels, maintain product availability stability, and continue to prioritise cost efficiency across all lines while upholding high quality standards and regulatory compliance.
“Various strategic steps have successfully maintained sustainable profitability. After successfully turning from a loss in 2024 to profit in 2025, we continue to strive to maintain the company’s profitability,” she explained.
She stated that in response to the impact of geopolitics causing rises in raw material prices and costs, the company has mitigated risks through purchase contracts since the beginning of the year and continues to monitor developments to remain adaptive.
The aim is to secure the sales, cost, and net profit targets until the end of the year in line with the RKAP.
Ida continued that branded generic medicines (OGB) became one of the supports for sales growth in January-March 2026.
OGB sales in the first quarter of 2026 surged 59% to Rp128.70 billion compared to the same period last year of Rp80.88 billion.
The contribution of anti-tuberculosis (TB) medicines for adults and children, as well as blood supplement tablets, which are important government programmes related to TB, anaemia, and stunting, represents Phapros’s commitment to improving the health of Indonesian society.